Efficacy and acceptability of atypical antipsychotics for the treatment of post-traumatic stress disorder: A meta-analysis of randomized, double-blind, placebo-controlled clinical trials

Psychiatry Research

Volumn 219, Issue 3, 2014, Pages 543-549

  Liu, Xiao hui ^a   Xie, Xin hui ^a,b,c   Wang, Ke yong ^d   Cui, Hong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b SHENZHEN KANGNING HOSPITAL   (China)

^c Shenzhen Key laboratory of psychological health center   (China)

^d Anhui Mental Health Center   (China)

Author keywords

Atypical antipsychotics; Meta analysis; Pharmacotherapy; Post traumatic stress disorder; Randomized controlled trial

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; PLACEBO; RISPERIDONE; NEUROLEPTIC AGENT;

ARTICLE; BATTLE INJURY; CHILD ABUSE; CLINICIAN ADMINISTERED PTSD SCALE; DOMESTIC VIOLENCE; DRUG EFFICACY; HUMAN; META ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; PHYSICAL ABUSE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SENSITIVITY ANALYSIS; SEXUAL ABUSE; SEXUAL ASSAULT; DOUBLE BLIND PROCEDURE; PATIENT ATTITUDE; PSYCHOLOGY; STRESS DISORDERS, POST-TRAUMATIC;

ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; HUMANS; PATIENT ACCEPTANCE OF HEALTH CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STRESS DISORDERS, POST-TRAUMATIC;

EID: 84907597245     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2014.05.027     Document Type: Article

References (47)

1. Ahearn E.P., Juergens T., Cordes T., Becker T., Krahn D. A review of atypical antipsychotic medications for posttraumatic stress disorder. International Clinical Psychopharmacology 2011, 26:193-200.
2. Ahearn E.P., Krohn A., Connor K.M., Davidson J.R. Pharmacologic treatment of posttraumatic stress disorder: a focus on antipsychotic use. Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists 2003, 15:193-201.
3. Albucher R.C., Liberzon I. Psychopharmacological treatment in PTSD: a critical review. Journal of Psychiatric Research 2002, 36:355-367.
4. American Psychiatric Association, 2000. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR, 4th ed. (text revision). APA, Washington, DC.
5. Ashraf R., Shahid M.A. Radioaerosol mucociliary clearance of tracheobronchial tree in normal subjects and in patients with respiratory diseases. JPMA. The Journal of the Pakistan Medical Association 1992, 42:40-42.
6. Asnis G.M., Friedman T.A., Sanderson W.C., Kaplan M.L., van Praag H.M., Harkavy-Friedman J.M. Suicidal behaviors in adult psychiatric outpatients, I: description and prevalence. The American Journal of Psychiatry 1993, 150:108-112.
7. Asnis G.M., Kohn S.R., Henderson M., Brown N.L. SSRIs versus non-SSRIs in post-traumatic stress disorder: an update with recommendations. Drugs 2004, 64:383-404.
8. Bartzokis G., Lu P.H., Turner J., Mintz J., Saunders C.S. Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biological Psychiatry 2005, 57:474-479.
9. Berger W., Mendlowicz M.V., Marques-Portella C., Kinrys G., Fontenelle L.F., Marmar C.R., Figueira I. Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: a systematic review. Progress in Neuro-psychopharmacology &Biological Psychiatry 2009, 33:169-180.
10. Blake D.D., Weathers F.W., Nagy L.M., Kaloupek D.G., Gusman F.D., Charney D.S., Keane T.M. The development of a c-administered PTSD scale. Journal of Traumatic Stress 1995, 8:75-90.
11. Braakman M.H., Kortmann F.A., van den Brink W. Validity of 'post-traumatic stress disorder with secondary psychotic features': a review of the evidence. Acta Psychiatrica Scandinavica 2009, 119:15-24.
12. Posttraumatic Stress Disorder: a Comprehensive Text 1999, Vol. xiv:103-143. Allyn & Bacon, Needham Heights, MA, US, 434.
13. Carey P., Suliman S., Ganesan K., Seedat S., Stein D.J. Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study. Human Psychopharmacology 2012, 27:386-391.
14. Charney D.S. Psychobiological mechanisms of resilience and vulnerability: implications for successful adaptation to extreme stress. The American Journal of Psychiatry 2004, 161:195-216.
15. Davidson J., Baldwin D., Stein D.J., Kuper E., Benattia I., Ahmed S., Pedersen R., Musgnung J. Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Archives of General Psychiatry 2006, 63:1158-1165.
16. Davidson J.R., Hughes D., Blazer D.G., George L.K. Post-traumatic stress disorder in the community: an epidemiological study. Psychological Medicine 1991, 21:713-721.
17. Foa E.B., Keane T.M., Friedman M.J. Guidelines for treatment of PTSD. Journal of Traumatic Stress 2000, 13:539-588.
18. Gao K., Muzina D., Gajwani P., Calabrese J.R. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. The Journal of Clinical Psychiatry 2006, 67:1327-1340.
19. Gupta S., Masand P. Aripiprazole: review of its pharmacology and therapeutic use in psychiatric disorders. Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists 2004, 16:155-166.
20. Hamner M.B. Psychotic features and combat-associated PTSD. Depression and Anxiety 1997, 5:34-38.
21. Hamner M.B., Robert S. Emerging roles for atypical antipsychotics in chronic post-traumatic stress disorder. Expert Review of Neurotherapeutics 2005, 5:267-275.
22. Hamner M.B., Robert S., Frueh B.C. Treatment-resistant posttraumatic stress disorder: strategies for intervention. CNS Spectrums 2004, 9:740-752.
23. Hetrick S.E., Purcell R., Garner B., Parslow R. Combined pharmacotherapy and psychological therapies for post traumatic stress disorder (PTSD). Cochrane Database Systematic Reviews 2010.
24. Ipser J., Seedat S., Stein D.J. Pharmacotherapy for post-traumatic stress disorder - a systematic review and meta-analysis. South African Medical Journal 2006, 96:1088-1096.
25. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., McQuay H.J. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996, 17:1-12.
26. Kessler R.C., Sonnega A., Bromet E., Hughes M., Nelson C.B. Posttraumatic stress disorder in the national comorbidity survey. Archives of General Psychiatry 1995, 52:1048-1060.
27. Kozaric-Kovacic D. Psychopharmacotherapy of posttraumatic stress disorder. Croatian Medical Journal 2008, 49:459-475.
28. Kozaric-Kovacic D., Pivac N., Muck-Seler D., Rothbaum B.O. Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial. The Journal of Clinical Psychiatry 2005, 66:922-927.
29. Krystal J.H., Rosenheck R.A., Cramer J.A., Vessicchio J.C., Jones K.M., Vertrees J.E., Horney R.A., Huang G.D., Stock C. Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial. JAMA: the Journal of the American Medical Association 2011, 306:493-502.
30. Padala P.R., Madison J., Monnahan M., Marcil W., Price P., Ramaswamy S., Din A.U., Wilson D.R., Petty F. Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women. International Clinical Psychopharmacology 2006, 21:275-280.
31. Pae C.U., Lim H.K., Peindl K., Ajwani N., Serretti A., Patkar A.A., Lee C. The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. International Clinical Psychopharmacology 2008, 23:1-8.
32. Petty F., Brannan S., Casada J., Davis L.L., Gajewski V., Kramer G.L., Stone R.C., Teten A.L., Worchel J., Young K.A. Olanzapine treatment for post-traumatic stress disorder: an open-label study. International Clinical Psychopharmacology 2001, 16:331-337.
33. Pivac N., Kozaric-Kovacic D., Muck-Seler D. Olanzapine versus fluphenazine in an open trial in patients with psychotic combat-related post-traumatic stress disorder. Psychopharmacology 2004, 175:451-456.
34. Reich D.B., Winternitz S., Hennen J., Watts T., Stanculescu C. A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. The Journal of Clinical Psychiatry 2004, 65:1601-1606.
35. Resnick H.S., Kilpatrick D.G., Dansky B.S., Saunders B.E., Best C.L. Prevalence of civilian trauma and posttraumatic stress disorder in a representative national sample of women. Journal of Consulting and Clinical Psychology 1993, 61:984-991.
36. Rothbaum B.O., Killeen T.K., Davidson J.R., Brady K.T., Connor K.M., Heekin M.H. Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder. The Journal of Clinical Psychiatry 2008, 69:520-525.
37. Schnurr P.P., Friedman M.J., Bernardy N.C. Research on posttraumatic stress disorder: epidemiology, pathophysiology, and assessment. Journal of Clinical Psychology 2002, 58:877-889.
38. Schoenfeld F.B., Marmar C.R., Neylan T.C. Current concepts in pharmacotherapy for posttraumatic stress disorder. Psychiatric Services 2004, 55:519-531.
39. Shevlin M., Armour C., Murphy J., Houston J.E., Adamson G. Evidence for a psychotic posttraumatic stress disorder subtype based on the national comorbidity survey. Social Psychiatry and Psychiatric Epidemiology 2011, 46:1069-1078.
40. Southwick S.M., Krystal J.H., Bremner J.D., Morgan C.A., Nicolaou A.L., Nagy L.M., Johnson D.R., Heninger G.R., Charney D.S. Noradrenergic and serotonergic function in posttraumatic stress disorder. Archives of General Psychiatry 1997, 54:749-758.
41. Steckler T., Risbrough V. Pharmacological treatment of PTSD - established and new approaches. Neuropharmacology 2012, 62:617-627.
42. Stein M.B., Kline N.A., Matloff J.L. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. The American Journal of Psychiatry 2002, 159:1777-1779.
43. Sullivan G.M., Neria Y. Pharmacotherapy in post-traumatic stress disorder: evidence from randomized controlled trials. Current Opinion in Investigational Drugs 2009, 10:35-45.
44. Ursano R.J., Bell C., Eth S., Friedman M., Norwood A., Pfefferbaum B., Pynoos J.D., Zatzick D.F., Benedek D.M., McIntyre J.S., Charles S.C., Altshuler K., Cook I., Cross C.D., Mellman L., Moench L.A., Norquist G., Twemlow S.W., Woods S., Yager J. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. The American Journal of Psychiatry 2004, 161:3-31.
45. Vieweg W.V., Julius D.A., Fernandez A., Beatty-Brooks M., Hettema J.M., Pandurangi A.K. Posttraumatic stress disorder: clinical features, pathophysiology, and treatment. The American Journal of Medicine 2006, 119:383-390.
46. World Health Organization (WHO), 1992. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines.
47. Zohar J., Amital D., Miodownik C., Kotler M., Bleich A., Lane R.M., Austin C. Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. Journal of Clinical Psychopharmacology 2002, 22:190-195.